Video series Residual Vascular Risk What are the limitations of the fibrate trials in residual vascular risk? 2018 – Jean-Charles Fruchart Residual Risk: The need for a step beyond lower is better 2008 – Jean-Charles Fruchart Why do we need a new consensus on residual vascular risk? Has the risk profile changed? 2018 – Raoul Santos What is residual vascular risk? 2018 – Henry Ginsberg Why do we need a new consensus on residual vascular risk? Has the risk profile changed? 2018 – Raoul Santos What is residual vascular risk? 2018 – Henry Ginsberg What is residual vascular risk – and what are the markers of this risk? 2018 – Chris Packard What is changing in our management of residual vascular risk? 2018 – Aruna Pradhan How do we identify which patients benefit most from additional intervention beyond current treatment? 2018 – Aruna Pradhan What can we learn from past clinical trials to test new agents for residual vascular risk? 2018 – Aruna Pradhan ESC 2017 Dr Ridker discusses the evolution of residual cardiovascular risk 2017 – Paul Ridker Can changes in lifestyle impact residual vascular risk? 2014 – César Rodríguez Gilabert How would you differentiate vascular risk and residual vascular risk: how do you address each risk? 2014 – César Rodríguez Gilabert How can you explain the residual risk observed in TNT and PROVE IT? 2013 – Alberto Zambon Is residual risk clinically relevant? 2013 – Antony Keech Pharmacological Reduction of Residual Vascular Risk: What can we expect from pharmacological reduction of hypertriglyceridemia? 2009 – Robert Rosenson Pharmacological Reduction of Residual Vascular Risk: What is the impact of hypertriglyceridemia on LDL particles? 2009 – Robert Rosenson Pharmacological Reduction of Residual Vascular Risk: How can we be successful in getting individuals treated with Niacin? 2009 – Robert Rosenson Global Challenge of Residual Vascular Risk: TG/HDL-C the forgotten factor 2009 – Jean Davignon Global Challenge of Residual Vascular Risk: Deep inside the plaque 2009 – Jean Davignon Pharmacological Reduction of Residual Vascular Risk: Do we have outcome data with Niacin? 2009 – Robert Rosenson Pharmacological Reduction of Residual Vascular Risk: What are the effects of fibrates on lipoproteins? 2009 – Robert Rosenson Current Evidence on Factors Producing Residual Vascular Risk: Why is non HDL-C a candidate secondary target in patients with high triglyceride? 2009 – Virgil Brown Current Evidence on Factors Producing Residual Vascular Risk: Do HDL cholesterol levels predict risk in statin trials? 2009 – Virgil Brown Current Evidence on Factors Producing Residual Vascular Risk: Do triglycerides (TG) levels predict risk in statin trials? 2009 – Virgil Brown Current Evidence on Factors Producing Residual Vascular Risk: What are the modifiable risk factors? 2009 – Virgil Brown Background: statin therapy leaves a hudge Residual vascular Risk 2009 – Frank Sacks Residual risk mission 2009 – Khalid Al-Rubeaan, Vladimir Christov, Gheorghe Andrei Dan, Michel Hermans, Masato Odawa New insights into Lipid-Related Residual Vascular Risk 2009 – Mike Gibbs Future approaches to managing vascular risk 2009 – Robert Rosenson, Christoph Wanner, Gheorghe Andrei Dan, Khalid Al-Rubeaan, Virgil Brown Residual Risk in Women 2009 – Sonia Anand, Henry Ginsberg, Lale Tokgozoglu Residual Risk, are we treating too late? 2009 – Virgil Brown, Michael Brown, Jean Davignon, Michel Hermans, Frank Sacks What is the Rationale for Looking at the Residual Vascular Risk? 2009 – Virgil Brown Managing Residual vascular Risk today 2009 – Alberto Zambon What is the role of excess number of LDL particles in the Residual vascular Risk? 2008 – Robert Rosenson What is the residual risk observed in the PROVE IT study which compared pravastatin 40 mg to atorvastatin 80 mg in acute coronary syndrome patients? 2008 – Peter Kwiterovitch, Christopher Cannon R3i project activities: An ambitious program of education and communication 2008 – Bart Staels, Alberto Zambon After results of intensive glucose lowering therapy in the ACCORD study, what is the best goal level for lowering HbA1c? 2008 – Paola Fioretto, Michel Hermans R3i project activities: An ambitious program of education and communication 2008 – Bart Staels, Alberto Zambon After results of intensive glucose lowering therapy in the ACCORD study, what is the best goal level for lowering HbA1c? 2008 – Paola Fioretto, Michel Hermans The STENO-2 study: addressing the issue of Residual Risk 2008 – Paola Fioretto Who is at risk of Residual Vascular Risk? 2008 – Michel Hermans, Alberto Zambon Residual risk definition 2008 – Paola Fioretto, Robert Rosenson, Frank Sacks, Bart Staels How Can we Reduce the Residual Risk? 2008 – Bryan Brewer Why Should we Focus on Residual Risk? 2008 – Bryan Brewer How to Better Identify Patients at Cardiovascular Residual Risk? 2008 – Vijay Nambi, Anand Rohatgi Which Biological Targets for Macrovascular Residual Risk Management? 2008 – Christie Ballantyne, Peter Kwiterovitch Residual Risk Reduction Strategy 2008 – Bryan Brewer, Christopher Cannon, Peter Kwiterovitch Communicating about cardiovascular risk 2008 – Lorie Mosca, Jarett Berry A call to action from the ISC Officers 2008 – Jean-Charles Fruchart, Michel Hermans
